Hsu CL, Su YY, Ou DL, Hsu C, et al. Reply to: "Comment on nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration". J Hepatol 2025 Dec 8:S0168-8278(25)02713-8. doi: 10.1016/j.jhep.2025.
PMID: 41371347